Table 2.
Available studies on MRD detection by MFC provides strong prognostic information in AML after both induction and consolidation therapy.
| Study | Patients (n) | Timepoint | Multivariate Analysis | Threshold Post-IND | Threshold Post-CONS | Method | Details on Survival Parameters |
|---|---|---|---|---|---|---|---|
| [44] | 53 | I, C | I, C | 0.5% | 0.2% | NA | |
| [45] | 56 | I, C | C | 0.45% | 0.035% | Empirical | |
| [46] | 126 | I | I | <0.01%, | NA | NA | MRD > 1%: 3-year RR: 85% |
| 0.01–0.1%, | MRD 0.1–1.0%: 3-year RR: 45% | ||||||
| 0.1–1%, | MRD 0.01–0.1%: 3-year RR: 14% | ||||||
| >1% | MRD <0.01%: 3-year RR: 0% | ||||||
| [47] | 62 | I, C | C | Continuous analysis log-difference | Continuous analysis log-difference | 75th percentiles of log-difference | |
| [48] | 106 | Day 16 after I | Day 16 after I | Continuous analysis log-difference | NA | Median of log-difference | |
| [49] | 100 | I, C | C | 0.035% | 0.035% | Maximally selected log-rank statistics | 5-year RFS 72% (MRD neg) vs. 11% (MRD pos) |
| [39] | 142 | I, C | C | 0.035% | 0.035% | Maximally selected log-rank statistics | 5-year RFS 60% (MRD neg) vs. 16% (MRD pos) |
| [50] | 54 | I | I | 0.15% | 0.15% | ROC analysis | |
| [40] | 241 | I 1, I 2, C | I 2 | 0.1% | 0.1% | NA | Cutoff points between 0.05 and 0.8 are all significant |
I: induction; C: Consolidation; NA: not available; MRD: minimal residual disease; RR: risk of relapse; RFS: relapse free survival; ROC: receiver operating characteristics.